This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2009 Jan;33(1):92-3.

doi: 10.1016/j.ijantimicag.2008.06.014. Epub 2008 Sep 11.

Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis

Hae-Seong Nam, Won-Jung Koh, O Jung Kwon, Sang-Nae Cho, Tae Sun Shim

PMID: 18789655
DOI: 10.1016/j.ijantimicag.2008.06.014

Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis

Hae-Seong Nam et al. Int J Antimicrob Agents. 2009 Jan.

. 2009 Jan;33(1):92-3.

doi: 10.1016/j.ijantimicag.2008.06.014. Epub 2008 Sep 11.

Authors

Hae-Seong Nam, Won-Jung Koh, O Jung Kwon, Sang-Nae Cho, Tae Sun Shim

PMID: 18789655
DOI: 10.1016/j.ijantimicag.2008.06.014

No abstract available

PubMed Disclaimer

Similar articles

Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
Sotgiu G, Lange C, Richardson MD, Matteelli A, Centis R, Eker B, Guenther G, Spanevello A, Migliori GB; TBNET. Sotgiu G, et al. J Antimicrob Chemother. 2009 Oct;64(4):879-83; author reply 883-4. doi: 10.1093/jac/dkp265. Epub 2009 Aug 3. J Antimicrob Chemother. 2009. PMID: 19651787 No abstract available.
Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
Yew WW, Chang KC, Chau CH. Yew WW, et al. J Antimicrob Chemother. 2009 Nov;64(5):1119; author reply 1119-20. doi: 10.1093/jac/dkp291. Epub 2009 Aug 8. J Antimicrob Chemother. 2009. PMID: 19666903 No abstract available.
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.
Koh WJ, Shim TS. Koh WJ, et al. J Antimicrob Chemother. 2009 Nov;64(5):1119-20. doi: 10.1093/jac/dkp344. Epub 2009 Sep 10. J Antimicrob Chemother. 2009. PMID: 19744986 No abstract available.
[The analysis of clinical data about the treatment of linezolid against tuberculosis].
Nie WJ, Chu NH. Nie WJ, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2013 Aug;36(8):601-3. Zhonghua Jie He He Hu Xi Za Zhi. 2013. PMID: 24252739 Review. Chinese. No abstract available.
[Linezolid for pediatric infections].
Moulin F, Hériveaux B, Vallet C. Moulin F, et al. Arch Pediatr. 2010 Jun;17(6):762-3. doi: 10.1016/S0929-693X(10)70098-1. Arch Pediatr. 2010. PMID: 20654880 Review. French. No abstract available.

See all similar articles

Cited by

Current development and future prospects in chemotherapy of tuberculosis.
Nuermberger EL, Spigelman MK, Yew WW. Nuermberger EL, et al. Respirology. 2010 Jul;15(5):764-78. doi: 10.1111/j.1440-1843.2010.01775.x. Epub 2010 Jun 4. Respirology. 2010. PMID: 20546189 Free PMC article. Review.
Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
Alffenaar JW, van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AM, van Soolingen D, Kosterink JG, Uges DR, van der Werf TS. Alffenaar JW, et al. Clin Pharmacokinet. 2010 Aug;49(8):559-65. doi: 10.2165/11532080-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20608757 Clinical Trial.
Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.
Zhang X, Falagas ME, Vardakas KZ, Wang R, Qin R, Wang J, Liu Y. Zhang X, et al. J Thorac Dis. 2015 Apr;7(4):603-15. doi: 10.3978/j.issn.2072-1439.2015.03.10. J Thorac Dis. 2015. PMID: 25973226 Free PMC article.
Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.
Alffenaar JW, van der Laan T, Simons S, van der Werf TS, van de Kasteele PJ, de Neeling H, van Soolingen D. Alffenaar JW, et al. Antimicrob Agents Chemother. 2011 Mar;55(3):1287-9. doi: 10.1128/AAC.01297-10. Epub 2011 Jan 3. Antimicrob Agents Chemother. 2011. PMID: 21199931 Free PMC article.
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.
Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, Zhu T, Mitton-Fry M, Ladutko L, Campbell S, Miller PF. Wallis RS, et al. Antimicrob Agents Chemother. 2011 Feb;55(2):567-74. doi: 10.1128/AAC.01179-10. Epub 2010 Nov 15. Antimicrob Agents Chemother. 2011. PMID: 21078950 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science